The EPS beat is likely to be viewed positively as it suggests that Legend Biotech is managing its costs effectively and possibly improving its operational efficiency. However, the sales miss is significant and could raise concerns about the company's market position or execution capabilities. The mixed results may lead to short-term volatility in the stock as investors digest the implications of the earnings report.